Translate Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2011-01-01
- Employees
- 122
- Market Cap
- -
- Website
- http://translate.bio
Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency
Phase 1
Withdrawn
- Conditions
- Ornithine Transcarbamylase Deficiency
- Interventions
- Biological: MRT5201Other: Placebo
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Translate Bio, Inc.
- Registration Number
- NCT03767270
Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Translate Bio, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03375047
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath